Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of
PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on
combination antiretroviral therapy.
Consenting subjects will be shifted from their combination antiretroviral regimen to PRO 140
monotherapy for 12 weeks. Total treatment duration with PRO 140 will be 14 weeks with the one
week overlap of existing retroviral regimen and PRO 140 at the beginning of the study
treatment, and one week overlap at the end of the treatment in subjects who do not experience
virologic failure.
Phase:
Phase 2
Details
Lead Sponsor:
CytoDyn, Inc.
Treatments:
HIV Antibodies Leronlimab PRO-140 monoclonal antibody